Baxter signs British flu vaccine deal

Aug 17, 2007

Baxter International said it has entered into an agreement to supply Britain with flu vaccine in the event of a bird flu pandemic.

The Deerfield, Ill., company is in the final stages of testing for a vaccine against H5N1 strains of avian influenza.

Baxter said it will manufacture its pandemic vaccine in a serum-free, vero cell-based system that accelerates vaccine availability. The company said vaccines produced using this process can be released within approximately 12 weeks, significantly earlier than with traditional egg-based systems.

The vero cell culture gives the company the flexibility to quickly respond to emerging variant pandemic virus strains, Baxter said in a news release.

The Chicago Tribune said the advanced supply agreement could be worth tens of millions of dollars to the company over the next four years.

British health officials said they signed more than $300 million in contracts with Baxter and GlaxoSmithKline to supply a vaccine as soon as the strain is identified by the World Health Organization.

Copyright 2007 by United Press International

Explore further: FDA approves new drug for rare genetic disease

add to favorites email to friend print save as pdf

Related Stories

Expert panel to view confidential swine flu papers

May 19, 2010

(AP) -- An expert panel investigating the World Health Organization's response to last year's swine flu outbreak said Wednesday it wants to see confidential exchanges between the U.N. body and drug companies.

EU drug agency: License 2 swine flu vaccines

Sep 25, 2009

(AP) -- The European Union's drug regulator recommended Friday that two swine flu vaccines be licensed in the 27-nation bloc to ensure their availability before the start of the normal flu season.

Europe fast-tracking swine flu vaccine

Jul 26, 2009

(AP) -- In a drive to inoculate people against swine flu before winter, many European governments say they will fast-track the testing of a new flu vaccine, arousing concern among some experts about safety ...

Fight for swine flu vaccine could get ugly

Jul 16, 2009

(AP) -- An ugly scramble is brewing over the swine flu vaccine - and when it becomes available, Britain, the United States and other nations could find that the contracts they signed with pharmaceutical companies are easily ...

Recommended for you

Boxed warnings are common in novel therapeutics

18 hours ago

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

19 hours ago

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

20 hours ago

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments : 0